Long-Term Bimekizumab Data Confirm Sustained Efficacy, Consistent Safety in Hidradenitis Suppurativa: Steven Daveluy, MD

Why It Matters

Sustained flare‑free control and a stable safety record position bimekizumab as a compelling long‑term option for HS, potentially shifting treatment paradigms toward earlier biologic intervention.

Key Takeaways

• 86% of patients stayed flare‑free over three years
• Early treatment yields better outcomes than late-stage disease
• Safety profile unchanged from week 16 through year 3
• Bimekizumab efficacy compares favorably to secukinumab, adalimumab
• No new safety signals observed in long‑term data

Pulse Analysis

Hidradenitis suppurativa (HS) remains one of dermatology’s most challenging chronic inflammatory disorders, affecting up to 1% of the adult population and imposing severe pain, scarring, and psychosocial burden. Traditional therapies often provide only partial relief, prompting a surge in biologic development. Bimekizumab, a dual IL‑17A/F inhibitor, entered the HS arena with the promise of deeper pathway blockade, differentiating it from single‑target agents like adalimumab. As insurers and providers weigh cost against clinical benefit, long‑term efficacy and safety data become decisive factors in formulary decisions.

The three‑year BE HEARD program delivers the most durable efficacy signal yet reported for an HS biologic: 86.1% of participants experienced no flares throughout the study. This durability is especially notable given the disease’s propensity for recurrent lesions. Moreover, subgroup analysis highlighted a “window of opportunity” – patients with Hurley Stage 2 disease and shorter disease duration achieved superior outcomes, underscoring the clinical advantage of initiating therapy early. While direct comparative trials are absent, the sustained response aligns favorably with real‑world performance of secukinumab and adalimumab, suggesting bimekizumab could become a first‑line biologic for appropriately selected patients.

Safety considerations are paramount for chronic biologic use. Over three years, bimekizumab’s adverse‑event profile remained flat, mirroring early‑phase observations and showing no emergent signals. This consistency reassures clinicians and payers about long‑term risk, a critical component for chronic disease management and for negotiating value‑based contracts. As the HS treatment landscape evolves, the combination of high flare‑free rates, early‑treatment benefits, and a stable safety record positions bimekizumab to reshape therapeutic algorithms and potentially improve quality of life for millions of patients.